RxDoctor Payments Data

Nidal Boutros

Internal Medicine · Lebanon, MONPI 1629036173

Payments from drug & device makers

$4,880in general payments, 2019–2025

Across 306 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Pfizer$572
  • Novo Nordisk$508
  • AstraZeneca$348
  • Lilly USA, LLC$290
  • Amgen$279
  • plus $2K from 35 others

What the payments were for

  • Food & beverage$4,880100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,880 in reported general payments places this provider in the 85th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$136,835
Medicare patients
376
Services billed
4,558

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide157$170,131
FarxigaDapagliflozin Propanediol82$82,956
JardianceEmpagliflozin93$80,316
OzempicSemaglutide65$69,154
EliquisApixaban59$63,375
TrulicityDulaglutide51$58,992
JanuviaSitagliptin Phosphate45$47,976
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$38,344
XareltoRivaroxaban37$26,364
VascepaIcosapent Ethyl29$8,515
Incruse ElliptaUmeclidinium Bromide23$8,010
Atorvastatin Calcium837$7,561
Repatha PushtronexEvolocumab12$6,966
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$6,116
Tresiba Flextouch U-100Insulin Degludec12$5,769

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$290$229,123208 claims
AstraZenecaFarxiga, Symbicort$348$87,50398 claims
Boehringer IngelheimJardiance$122$80,31693 claims
Novo NordiskOzempic$508$69,15465 claims
PfizerEliquis, Paxlovid$572$66,16977 claims
MerckJanuvia, Janumet Xr$118$53,35856 claims
GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta$88$51,72989 claims
Johnson & JohnsonXarelto$106$26,36437 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$11$3,498433 claims
AbbVieSynthroid$1,036$2,04433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Lebanon

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →